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The majority of breast cancers are oestrogen dependent and although current treatment strategies have improved, approximately
50% of the patients will develop metastasis. New treatments that result in long-term systemic immunity are therefore being
developed. We have previously shown that adenoviral gene transfer of B7-1/IL-2 to murine breast cancer induces a high rate of
complete tumour regression and systemic immunity. Since oestrogens not only affect breast cancer but also have been shown to
modulate immune function and secretion of immune-regulatory cytokines, we explored whether administration of oestradiol altered
the immune response induced by an adenoviral vector expressing B7-1/IL-2. An oestrogen-dependent murine breast cancer tumour
was used in ovariectomised mice, supplemented either oestradiol or placebo. We report the somewhat unexpected finding that
intratumoral injection of adenovirus expressing B7-1/IL-2 induces complete tumour regression in 76% of oestradiol-supplemented
mice, while only 18% of the tumours regressed in the oestrogen-depleted group. Cured mice in both groups exhibited a similar CTL
response against the tumour antigen. However, intratumoral IFN-g levels, 2 days after B7-1/IL-2 injection, were significantly higher in
mice treated with oestradiol compared to placebo. This may be one mechanism explaining the higher response rate of tumours in
oestradiol-replenished mice.
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Breast cancer accounts for almost 30% of all cancer cases in
women in the Western World and the incidence of the disease is
still increasing (Ries et al, 2001). Oestrogen exposure plays an
important role in the risk of developing breast cancer. Prolonged
exposure of sex steroids increase the risk, while surgically induced
menopause by bilateral ovariectomy reduces the risk of the disease
(Schairer et al, 1997; Rossouw et al, 2002). Approximately 70% of
all breast cancers express the oestrogen receptor (ER), and
treatments designed to block oestrogen effects in the breast are
important options in the clinic (Lapidus et al, 1998). However,
50% of women with primary tumours will develop metastasis and
eventually die from the disease (Klijn et al, 1992). Therefore, new
treatments such as immunogene therapy that results in long-term
systemic immunity, which may prevent metastatic disease, are
being developed.
Gene therapy enhancing the immune response against cancer
cells includes immunisation, introduction of cytokines and
expression of T-cell costimulatory molecules. Presentation of
antigen to the T-cell receptor is necessary for the initiation of an
immune response. However, additional molecules expressed on
antigen-presenting cells deliver essential costimulatory signals and
in the absence of costimulation T-cell anergy is developed. The B7
costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are
required for full activation of T cells. The B7 molecules are
members of the immunoglobulin (Ig) superfamily and are ligands
for CD28 and CTLA-4 counter-receptors on T cells (Brunet et al,
1987; Freeman et al, 1989, 1991; Linsley et al, 1990). Ligation of
CD28 with B7-1 or B7-2 results in upregulation of the IL-2 receptor
a, b and g chains (Cerdan et al, 1992, 1995), increased IL-2 gene
transcription (Fraser et al, 1991), upregulation of CTLA-4 mRNA
levels (Lindsten et al, 1993), cytokine secretion and T-cell
proliferation (Linsley et al, 1991; Freeman et al, 1993; Chambers,
2001). Expression of B7 family members in murine tumour models
has been shown to activate CD8þ T cells and/or CD4þ T cells
against tumour cells (Freeman et al, 1991, 1993; Townsend
and Allison, 1993). Administration of IL-2 has been shown to
promote antitumour immunity, presumably by alleviating the
anergic block seen in T cells in some tumour models and thereby
preventing the onset of anergy (Schwartz, 1990). We have
previously shown that an adenovirus vector expressing human
IL-2 causes complete tumour regression in approximately 20–40%
of the cases, whereas a simultaneous expression of B7-1 and IL-2 in
a single vector have a much higher success rate, 490% (Emtage
et al, 1998).
There are known gender differences in the immune response.
Women have an increased incidence of autoimmune diseases and a
better outcome after sepsis or trauma and oestrogens have been
shown to modulate immune function (Ansar Ahmed et al, 1985;
Schroder et al, 1998). Oral contraceptives and pregnancy alter the
course of many autoimmune diseases in women (Paavonen, 1994).
It has also been shown that oestrogens can regulate the expression
of IL-2, IL-6, IL-10 and IFN-g in several cell systems (Gilmore et al, Received 22 January 2003; revised 14 April 2003; accepted 1 May 2003
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s1997; Correale et al, 1998; Keck et al, 1998; Rogers and Eastell,
1998).
Given the impact oestrogens have on both breast cancer and the
immune function, the objective of this study was to explore
whether oestradiol altered the immune response induced by
intratumoral injection of an adenoviral vector expressing B7-1/IL-
2, in a murine oestrogen-dependent model of breast cancer.
In this study, we used ovariectomised mice supplemented with
physiologic levels of oestradiol or left oestrogen depleted. We
demonstrate that oestradiol supplementation results in markedly
enhanced tumour regression and that this is associated with raised
levels of intratumoral IFN-g.
MATERIALS AND METHODS
Animals and ovariectomy of mice
FVB/n mice (6–8 weeks old) were purchased from Charles River
(Troy, NY, USA). They were housed in pathogen-free conditions
with a light/dark cycle of 12/12h and fed with rodent chow and
water ad libitum. The McMaster University animal ethics research
board approved all animal work, which was conducted according
to the UKCCCR guidelines (Workman et al, 1998).
Mice were anaesthetised with isofluorane (Abbot), ovariecto-
mised (OVX) and 3-mm pellets containing 17 b-oestradiol (E2),
0.18mg per 60 day release, or placebo pellets (Innovative Research
of America, Sarasota, FL, USA) were implanted subcutaneously
(s.c.) in the animal’s back 7 days before tumour induction. The
pellets provide continuous release of E2 at serum concentrations of
150–250pM, confirmed by serum analysis assayed by Abbot
Axsym Systems (Abbot, IL, USA), which is in the range of
physiologic levels seen in mice during the oestrous cycle (Loeb and
Qiumby, 1987).
Polyoma middle T tumour model
Tumour cells were derived from a transgenic mouse strain
expressing polyoma middle T (PyMT) antigen under the control
of the mouse mammary tumour virus (MMTV) long-terminal
repeat (Guy et al, 1992). These mice develop spontaneous
adenocarcinomas of all mammary epithelium by 8–10 weeks of
age. These tumours were excised, minced and incubated at 371C
with gentle stirring in collagenase/dispase solution (25mg
collagenase 250mg dispase, Roche, in 100ml phosphate-buffered
saline (PBS) to generate a single-cell suspension, stored at  701C
in foetal bovine serum with 10% DMSO added. Thawed cells were
placed in complete F-11 medium and were cultured until they
reached confluence, usually 4–6 days. Thereafter, 1 10
6 cells in
200ml PBS were injected s.c. into the right hind flank of a syngenic
female FVB/n host. Tumour volume was determined by measuring
length, width, and depth of the tumour weekly using a caliper.
Recombinant adenoviruses
The vector expressing both human IL-2, known to be active across
species, and the murine costimulatory molecule B7-1(AdB7-1/IL-
2), and the control vector Addl70-3 were constructed as previously
described (Bett et al, 1994; Emtage et al, 1998).
Intratumour vector administration and rechallenge of
tumour-free mice
Following tumour formation (tumour volume o250mm
3) animals
were injected intratumorally with 1 10
9 PFU of AdB7-1/IL-2 or
control Addl70-3 vector diluted (50ml) in sterile endotoxin-free
PBS and tumour growth determined weekly. In animals that
showed complete regression of primary PyMT tumours, mice were
rechallenged at 90 days with PyMT tumour cells by subcutaneous
injection of 10
6 tumour cells on the opposite flank.
Cytotoxic T-cell assay
Specific PyMT antigen cytotoxic T-cell killing was measured as
previously described (Addison et al, 1998; Palmer et al, 2001).
Briefly, splenocytes were obtained from mice whose tumours had
regressed and had also resisted rechallenge and were restimulated
for 5 days by coculture with irradiated 516MT3 cells that express
the PyMT antigen. Cytotoxicity was determined by coculture with
516MT3 or PTO516 (PyMT antigen-negative cells) target cells,
labelled with
51Cr. The percent specific lysis was calculated as
follows: 100  (experimental c.p.m.  spontaneous c.p.m.) (max-
imal c.p.m.  spontaneous c.p.m.).
Quantification of murine IFN-c in tumour tissue and
plasma
Tumours were removed, snap frozen in liquid nitrogen, and
weighed 2 and 10 days after adenovirus administration. Tumours
were homogenised in PBS containing 100mM phenylmethylsulpho-
nyl fluoride, centrifuged and the supernatants were stored at
 701C for subsequent analysis. Plasma was collected by cardiac
puncture. IFN-g was measured using an ELISA kit (R&D Systems,
Minneapolis, MN, USA). The sensitivity was 2pgml
 1. All samples
were analysed in duplicates and given results are the means of each
duplicate.
Statistics
Data are expressed as mean7s.e. m. All given values represent the
mean of the duplicate analysis of each sample. Student’s t-test and
Fisher’s exact test was used as appropriate. A Po0.05 was
considered as statistically significant.
RESULTS
Enhanced tumour regression by oestradiol after
intratumoral administration AdB7-1/IL-2
We have recently characterised the oestrogenic phenotype of the
PyMT model used in this study. These tumours express the ER and
E2 stimulates tumour cell proliferation in vitro and tumour growth
in vivo (Dabrosin et al, 2003). Moreover, E2 enhances tumour
angiogenesis in vivo (Dabrosin et al, 2003). The recombinant
adenovirus vector expressing murine B7-1 and human IL-2 has
previously been characterised and expression of both molecules
have been confirmed (Emtage et al, 1998).
Administration of 1 10
9 PFU of the B7-1/IL-2 vector resulted
in complete tumour regression within 3 weeks in 76% of
OVXþE2-treated animals, while only 18% of the placebo animals
were cured. In the E2-treated group, all tumours showed either
partial or total regression with an overall response rate of 100%.
Partial regression was defined as stasis or decrease in tumour
volume 1 week after the administration of a vector, as compared
with the original tumour volume before treatment. In the OVX
animals without E2 supplement 60% of the tumours had a delayed
tumour growth without cure and 23% of the tumours failed to
respond at all. None of the tumours in OVX or OVXþE2 animals
treated with the control vector Addl70-3 had any response and
none of the mice were cured, a result that we previously have
reported in normal cycling mice (Emtage et al, 1998) (Table 1).
The survival data of all animals in this study are presented in
Figure 1. As previously shown, the cytokines delivered intratumo-
rally did mediate an effective immune response and tumour
regression, whereas systemic delivered cytokines fail to induce any
tumour response (Addison et al, 1995). The tumour size,
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3 for placebo tumours and 228760mm
3 E2-treated
tumours, was in the range previously described by our lab using
B7-1/IL-2 and other cytokines delivered to PyMT tumours by
adenoviral vectors (Addison et al, 1998; Emtage et al, 1998; Palmer
et al, 2001).
A few tumours in each group were allowed to grow considerably
larger before AdB7-1/IL-2 injection, OVXþplacebo 1170760mm
3
and E2 tumours 11507132mm
3. In these larger tumours, a partial
regression was induced by AdB7-1/IL-2 delivery to E2-treated
mice, while placebo mice continued to grow without delay
(Figure 2).
Oestradiol increased intratumoral IFN-c production
induced by AdB7-1/IL-2
At 2 days after intratumoral administration of AdB7-1/IL-2, both
E2-exposed tumours and placebo tumours had increased levels of
IFN-g compared with tumours injected with the control vector
Addl70-3, 2470.6pgmg
 1 tumour in AdB7-1/IL-2 vs
370.04pgmg
 1 tumour with the control vector. However,
tumours from E2-treated mice had significantly higher levels of
IFN-g compared with placebo-treated mice, 3470.6pgmg
 1
tumour vs 1070.3pgmg
 1 tumour, Po0.01, n¼3–4 in each
group (Figure 3). Tumour levels of IFN-g and the magnitude of the
increase in responders compared to nonresponders are in line with
the previous work (Bramson et al, 1996). The increased levels of
IFN-g were localised to the tumour since both groups had similar
plasma levels of IFN-g,5 2 75pgml
 1. At 10 days after vector
administration, the tumour levels of IFN-g in both groups had
decreased to 1.470.02pgmg
 1 tumour (Figure 3). There was no
difference between E2-treated and placebo mice in the control
group (Figure 3).
Table 1 Summary of responses of PyMT tumours following intratumoral injection of AdB7-1/IL-2 and
Addl70-3 in ovariectomised mice treated with placebo (OVX) or oestradiol (E2)
Treatment No response (%) Partial response (%) Total regression (%)
OVX control Addl70-3 5/5 (100) 0/5 (0) 0/5 (0)
OVX+E2 control Addl70-3 5/5 (100) 0/5 (0) 0/5 (0)
OVX AdB7-1/IL-2 5/22 (23) 13/22 (59) 4/22 (18)
OVX+E2 AdB7-1/IL-2 0/17 (0) 4/17 (24) 13/17 (76)*
Partial response refers to tumours that have undergone partial regression followed by regrowth, or a delay in growth; no
response refers to tumours that have continued to grow at a rate comparable to controls. *Po0.005 compared to OVX.
Figure 1 Long-term survival of ovariectomised (OVX) FVB/n mice
treated with oestradiol (E2) or placebo bearing small PyMT tumours
following treatment with recombinant adenovirus expressing B7-1/IL-2 or
control virus Addl70-3 at a dose of 1 10
9 PFU. OVXþE2-treated
tumours (228760mm
3) injected with AdB7-1/IL-2 (n¼17), OVXþ
placebo (160728mm
3) injected with AdB7-1/IL-2 (n¼22). Tumours
from both groups (OVX and OVXþE2, n¼10–11 in each group)
injected with the control virus Addl70-3, all succumbed to tumour growth.
(——) AdB7-1/IL-2 OVXþE2, (——) AdB7-1/IL-2 OVXþplacebo,
(— - –) Addl70-3 OVXþE2, (–––– ) Addl70-3 OVXþplacebo.
Figure 2 Survival of mice following intratumoral injection of large
tumours with recombinant adenovirus expressing B7-1/IL-2. Mice treated
as described in Figure 1. OVXþE2 (n¼3, initial size 11507132mm
3) and
OVXþplacebo (n¼3, 1170760mm
3) were injected with 1 10
9 PFU of
AdB7-1/IL-2. Control animals were injected with Addl70-3, 1 10
9 PFU
(n¼10 in each group with similar tumour sizes, 12307150mm
3, as the
treated tumours). (——) AdB7-1/IL-2 OVXþE2, (——) AdB7-1/IL-2
OVXþplacebo, (—-–)A d dl70-3 OVXþE2, (–––– )A d dl70-3
OVXþplacebo.
Figure 3 Oestradiol increased local IFN-g levels 2 days following
treatment with AdB-7/IL-2. Mice treated as described in Figure 1. IFN-g was
measured in tumour homogenate and normalised to the mass of tumour.
Oestradiol tumours treated with AdB7-1/IL-2 had significantly higher levels
of IFN-g on day 2, OVXþE2 n¼4, vs OVXþplacebo n¼3, *Po0.05.
There was no difference between the groups on days 0 and 10.
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sGeneration of long-term systemic immunity to PyMT
tumour cell rechallenge
Mice that had undergone complete regression of the PyMT
tumours after treatment with AdB7-1/IL-2 were rechallenged with
a second inoculation of 1 109 PyMT cells 90 days after initial
vector administration, on the left hind flank. None of the
challenged mice developed tumours and all remained tumour free
during the observation period (90 days). Naive mice simulta-
neously injected with the same tumour cell suspension developed
tumours within 21 days as expected. These results suggest that the
cured mice in either E2 or placebo group developed long-term
antitumour immunity after the AdB7-1/IL-2 treatment. These
results are in line with our previous data showing that cured mice
develop long-term immunity regardless of the cytokine vector
used, although the different vectors exhibit higher or lower
effectiveness in inducing complete tumour regression (Emtage
et al, 1998; Palmer et al, 2001).
CTL activity in cured mice
To determine whether oestradiol supplement may affect the
development of a tumour-specific CTL response, cured mice in
both the E2 and placebo group were killed and their spleens
removed 6 weeks following PyMT rechallenge. Splenocytes
prepared from either group demonstrated a 50% specific lysis of
516MT3 cells, expressing the PyMT antigen, at an effector to target
ratio of 90:1 (Figure 4). Minimal background was observed. This
suggests the presence of significant numbers of effector cells
capable of killing cells expressing the PyMT tumour antigen in
both treatment groups. Splenocytes from control mice did not
exhibit any tumour-specific CTL activity as previously shown
(Emtage et al, 1998).
DISCUSSION
In this study, we demonstrated that oestradiol, at physiologic
concentrations, enhances the immune response by intratumoral
adenoviral gene delivery of B7-1/IL-2 in a murine model of breast
cancer in which the growth rate is increased by oestrogen. This
difference was not due to an inability of oestrogen-depleted mice
to induce a CTL response since cured mice from both groups
exhibited similar CTL activity. However, we show that oestradiol
increased the local IFN-g response after delivery of AdB7-IL-2,
which may be one mechanism to explain the higher response rate
in the oestradiol-supplemented mice.
Distinct patterns of cytokine expression are associated with the
development of TH1 or TH2 immune responses (Mosmann and
Coffman, 1989; Mosmann and Sad, 1996). Development of CTL
response involves IL-2 and IFNg, while humoral responses are
associated with IL-4, IL-6 and IL-10. IFN-g is important for the
development of a potent antitumour response (Ogawa et al, 1998).
Our previous studies with the PyMT tumour model have shown
that lymphocytes isolated from cured mice exhibited raised levels
of IFN-g indicating that treatment with Ad vectors induces
cytokines and costimulatory molecules, which induce TH1-
mediated antitumour responses (Bramson et al, 1996; Addison
et al, 1998). Moreover, IFN-g affects tumour cells to be more
susceptible to T-cell-mediated killing (Gerrard et al, 1988) and
upregulates the chemokines IP-10 (interferon-inducibleprotein)
and MIG (monokine induced by gamma interferon) resulting in
decreased angiogenesis (Angiolillo et al, 1995; Palmer et al, 2001).
IFN-g also appears to sensitise human breast cancer cells to
undergo apoptosis (Ruiz-Ruiz et al, 2000).
It has been suggested that females produce stronger immune
reactions than males (Ansar Ahmed et al, 1985). Autoimmune
diseases such as multiple sclerosis and rheumatoid arthritis are
more frequent in women and patients go into a clinical remission
during pregnancy and exacerbate postpartum suggesting that the
immune response differs with various levels of oestrogen
(Ostensen et al, 1983; Confavreux et al, 1998). Oestradiol has
been found to modulate the secretion of cytokines from human
CD4þ cells, at physiological levels oestradiol increased IFN-g
production with no effect on IL-10 secretion (Gilmore et al, 1997).
However, at pharmacological levels or levels seen in pregnancy, the
IL-10 levels increased significantly, while IFN-g remained at the
same levels seen with a low dose of oestradiol (Gilmore et al, 1997).
Moreover, lymphocytes from female mice produce higher levels of
IFN-g after immune stimulation than those from males and an
oestrogen-responsive element in the IFN-g promoter in murine
spleen cells has been found (McFarland and Bigley, 1989; Fox et al,
1991). In addition, both oestrogen and B7molecules have the
ability to activate CD8þ cytotoxic cells even in the absence of
CD4þ (Stimson, 1988; Van Gool et al, 1996). However, other
mechanisms may also contribute in the higher response of
oestradiol treated tumours. We have recently shown that
oestradiol-treated PyMT tumours used in this experiment have a
higher microvessel count compared with tumours at the same size
grown in OVX mice with placebo supplement (Dabrosin et al,
2003). This could affect the access of the tumour cells to the
immune cells, that is, oestradiol-treated tumours have higher
blood flow and are thereby more available to the immune system.
None of the larger established tumours underwent complete
regression, but the tumours from oestradiol-treated mice showed a
partial response and delayed tumour growth. This suggests that
tumour size is a predictive factor for the success rate of immune
gene therapy and that a dose adjustment or other adjuvant
therapies are needed for treatment of heavy tumour burden. This is
in line with current clinical principles where tumour size is a
strong predictive factor for overall survival and relapse-free
interval and larger tumours are treated with surgery in combina-
tion radiotherapy and/or chemotherapy (Linderholm et al, 2000;
Bergh et al, 2001).
The results in our study are intriguing and somewhat
unexpected since the cornerstone of treatment of oestrogen-
dependent breast cancer is antioestrogen hormonal therapy.
However, the action of oestrogen in breast cancer is complex,
poorly understood and contradictory. While oestrogen stimulates
tumour cell growth in vitro at low doses, it inhibits proliferation at
Figure 4 Cytotoxic T lymphocyte activity in mice after total tumour
regression induced by AdB71/IL-2 treatment. Spleens were removed from
mice, which had undergone complete regression of PyMT breast cancer
tumours and not developed tumours after having been rechallenged with
fresh tumour cells. Splenocytes were used in a
51Cr release assay against
target cells (516MT3) with or without the PyMT antigen, PT0516 (-PyMT).
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shigh levels (Lippman et al, 1976). In vivo, breast tumours may
maintain high local levels of oestrogen independent on the overall
circulating concentration suggesting that added exogenous oestro-
gen has very little effect on the local tumour environment
(Blankenstein et al, 1992). Oestrogens have the ability to affect
tumour cell division, angiogenesis, bone density and the immune
system, and the overall result in vivo is dependent on the balance
between all these effects. Moreover, oestrogen effects are related to
the dose and type of hormone used. It is therefore important to use
physiologic levels of oestrogen and the naturally occurring E2 in
studies of pathogenesis and immune modulation.
We conclude that oestradiol increases the cure rate of oestrogen-
enhanced murine breast cancer treated with an intratumoral
adenoviral vector expressing B7-1/IL-2. Oestradiol treatment
increased the IFN-g levels in tumour tissue, measured 2 days after
tumour injection, which may be involved in the mechanisms
leading to the higher response rate in these mice. Future studies
will determine whether these data are valid for human breast
cancer and how the partial oestrogen agonist tamoxifen, the most
commonly used antioestrogen in breast cancer treatment, affects
immune-stimulatory breast cancer therapies.
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